3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Solid Tumours
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Liposarcoma
1
Leukemia, Hairy Cell
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Carcinoma
1
Interventions
Doxorubicin
27
Cyclophosphamide
26
Radiotherapy
16
Gemcitabine
16
Filgrastim
11
pembrolizumab
10
pazopanib
10
Radiation
9
Docetaxel
9
Cisplatin
9
fludarabine
7
Trabectedin
7
Ipilimumab
7
Ifosfamide
7
Granulocyte Colony-Stimulating Factor
7
Etoposide
7
Carboplatin
7
Busulfan
7
Bevacizumab
7
olaratumab
6
Temozolomide
6
Peripheral Blood Stem Cell Transplantation
6
Nivolumab
6
Mesna
6
Melphalan
6
selinexor
5
Leucovorin
5
Irinotecan
5
Celecoxib
5
Bortezomib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma
×
Famotidine
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled